Prevention of paediatric asthma and allergy by reduction of house dust mite content Source: Eur Respir J 2001; 18: Suppl. 33, 287s Year: 2001
OPURIT: O malizumab-p rotected u ltra r ush s pecific i mmunotherapy in severe asthmatic patients with house dust mite allergy Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011
Safety of subcutaneous immunotherapy with standardized extracts of house dust mite in allergic asthmatic subjects Source: Eur Respir J 2002; 20: Suppl. 38, 57s Year: 2002
Sublingual immunotherapy is an established therapy for house dust mite sensitive allergic rhinitis and/or asthma Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007
Impact of asthma-associated genetic polymorphisms on the efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021
Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
Clinical efficiency of sublingual and subcutaneous allergenspecific immunotherapy with household dust mite allergen in patients with persistent allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 438s Year: 2006
Hypoallergenic high dose scit as add-on therapy in children with allergic asthma caused by house dust mites Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009
House dust mite sublingual immunotherapy reduces type 2 biomarkers in allergic asthma Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
The effect of anti-mite mattress covers on mite allergen levels in the PIAMA (prevention and incidence of asthma and mite allergy) study Source: Eur Respir J 2001; 18: Suppl. 33, 321s Year: 2001
Association between dust mite sensitisation and asthma severity Source: Annual Congress 2010 - Clinical aspects of asthma and allergic respiratory diseases Year: 2010
Effects of 3-yr immunotherapy with standardised extracts of house dust mite in allergic asthmatic subjects receiving appropriate drug treatment Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002
House dust mite (HDM) avoidance and treatment of severe childhood asthma Source: Eur Respir J 2003; 22: Suppl. 45, 314s Year: 2003
The reduction of the house dust mite as a prevention component in a treatment of the asthmatic children Source: Eur Respir J 2002; 20: Suppl. 38, 335s Year: 2002
Diagnostic utility of serum periostin for house dust mite sublingual immunotherapy response in allergic rhinitis Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021
The association of adult bronchial responsiveness with IgE sensitisation and exposure to cat and house dust mite allergen Source: Eur Respir J 2006; 28: Suppl. 50, 145s Year: 2006
The effect of montelukast during allergen sensitization period in house dust mite mouse model Source: International Congress 2017 – "Alarming" immunological patterns in asthma Year: 2017
Calcaratarin D attenuates house dust mite-induced allergic asthma Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Allergen exposure in nondog and nonhouse dust mite sensitized atopic asthmatic subjects; effect on bronchial reactivity Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001
House dust mite allergen exposure is associated with sensitisation and asthma in New Zealand infants Source: Eur Respir J 2002; 20: Suppl. 38, 117s Year: 2002